Towards personalized computer simulations of breast cancer treatment by Köhn-Luque, Alvaro et al.
VPH2020 Conference – Paris 26-28 August 2020
Towards personalized computer simulation of breast
cancer treatment
Alvaro Ko¨hn-Luquea∗, Xiaoran Laia and Arnoldo Frigessia
aOslo Centre for Biostatistics and Epidemiology, University of Oslo, Norway,
Keywords multiscale modeling, hybrid cellular automaton, pharmacokinetics, pharmacodynamics, parallel
computing, approximate Bayesian computation
1. Introduction
Cancer pathology is unique to a given individual, and
developing personalized diagnostic and treatment pro-
tocols are a primary concern. Mathematical model-
ing and simulation is a promising approach to person-
alized cancer medicine. Yet, the complexity, hetero-
geneity and multiscale nature of cancer present se-
vere challenges. One of the major barriers to use
mathematical models to predict the outcome of ther-
apeutic regimens in a particular patient lies in their ini-
tialization and parameterization in order to reflect indi-
vidual cancer characteristics accurately.
Here we present a study where we used multitype
measurements acquired routinely on a single breast
tumor, including histopathology, magnetic resonance
imaging (MRI), and molecular profiling, to personalize
a multiscale hybrid cellular automaton model of breast
cancer treated with chemotherapeutic and antiangio-
genic agents. We model drug pharmacokinetics and
pharmacodynamics at the tumor tissue level but with
cellular and subcellular resolution. We simulate those
spatio-temporal dynamics in 2D cross-sections of tu-
mor portions over 12-week therapy regimes, resulting
in complex and computationally intensive simulations.
For such computationally demanding systems, for-
mal statistical inference methods to estimate individ-
ual parameters from data have not been feasible in
practice to until most recently, after the emergence
of machine learning techniques applied to likelihood-
free inference methods. Here we use the inference
advances provided by Bayesian optimization to fit our
model to simulated data of individual patients. In this
way, we investigate if some key parameters can be es-
timated from a series of measurements of cell density
in the tumor tissue, as well as how often the measure-
ments need to be taken to allow reliable predictions.
2. Methods
2.1 Patients and clinical data
To develop and validate our mathematical model we
used data from HER2-negative mammary carcinomas
from the NeoAva cohort [3], a randomized, phase II
clinical trial that evaluated the effect of bevacizumab
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in combination with neoadjuvant treatment regimes.
Four patients were selected to belong to both arms of
the trial and to have either a complete or no response
at 12 weeks of treatment. Details of baseline char-
acteristics, treatment, response and used clinical data
from all patients can be found in reference [2].
2.2 Multiscale mathematical model
We model the response of a cross-section of tumor
tissue to a combination of chemotherapeutic and an-
tiangiogenic drugs using a multiscale hybrid cellular
automaton. We combined tissue, cellular, extracel-
lular, and intracellular dynamics and informed them
by multitype, individual patient data. Figure 1 shows
an overview of the model structure and the different
model formalisms used. Full details are available in
reference [2].
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Figure 1: Multiscale hybrid cellular automaton struc-
ture
2.3 Bayesian optimization for likelihood-
free inference
For parameter inference we use an approximate
Bayesian computation method called Bayesian op-
timization for likelihood-free inference (BOLFI) [1].
BOLFI uses Gaussian processes to model the un-
known discrepancy function that compares the simu-
lations with the data via Bayesian optimization. Once
the probabilistic model has been inferred, it can be
used to approximate the true posterior distribution.
2.4 Simulation code
The open-source code to simulate the multiscale
mathematical model is written in Python 3.6.2 and
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available at bitbucket.org/xlai/codeavastin-py.git
3. Results
3.1 Simulation of observed treatment
outcomes
We first use our model to reproduce and elucidate the
treatment outcome of four patients. For each of them,
we run personalized simulations of different tumor por-
tions under the treatment received in the trial. Tumor
screening data at baseline (histopathology, MRI and
molecular data) are used to initialize and parameterize
the model together with other data available in the lit-
erature. We simulate 12 weeks of the spatio-temporal
dynamics of the considered tumor portion under the
effect of the applied drugs. We then use MRI examina-
tions at weeks 1 and 12 to compare with the simulated
outcomes. As an example, we illustrate in Figure 2-I a
simulation of a non-responder patient with low prolif-
erative cells able to scape the standard chemotherapy
regime administered every three weeks.
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Figure 2: Simulated time evolution of cancer cell density starting from di↵erent cell configura-
tions at week 0. Each line represents the average cancer cell density of 10 simulations, di↵ering
only in variables randomly drawn with certain probabilities, such as initialization of cell cycle
and killing in the model. The corresponding color band indicates the 95% bootstrap confidence
interval. Panel B of each figure shows the spatial distribution of cancer and stroma cells for a
representative simulation of the second cell configuration for each patient. Background color
represents oxygen concentration in mmHg.
Patient 3 is a non-responder. As we saw from DCE-MRI data, fig. 15 in the Supplementary
Material, the core of the tumor of this patient is poorly perfused, while the border is well
perfused, as seen from DCE-MRI data. Therefore we show, in fig. 3, model simulations that
reproduce the outcome of patient 3, representing a heterogenous perfusion profile.
We used the estimated values ktrans = 0.0067 /min and vp = 1.73% to reflect poorly-
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3.2 Simulation of alternative treatments
In addition to the regimes used in the clinical
study, we also tested multiple hypothetical alterna-
tive drug regimes (schedules and dos s) for the non-
responders. Figure 2-II shows a simulation of the
most successful schedule obtained for the same non-
responder patient shown in Figure 2-I. In that case
the drugs doses are reduced to a third of its orig-
inal ones, but administrated every week instead of
every 3 weeks. By means of the higher drug fre-
quency, low proliferative cells can no longer escape
the chemotherapy and the tissue becomes free of can-
cer cells after approximately 6 weeks of therapy.
3.3 Inference and predictions
Using the simulated number of cells from the patients
as measurements, BOLFI is able to accurately infer
up to three of the most relevant model parameters. In
fact, parameters were estimated well enough by using
only a few measurements made in the very beginning
of the therapy. Importantly, this was sufficient to pre-
dict the effect of the therapy regime at the end of the
12 weeks with good accuracy.
4. Conclusion
The use of mathematical models and simulations to
decide the best therapy for a cancer patient starts to
become a possibility. For breast cancer, we have been
able to develop and implement a first multiscale phar-
macokinetic and pharmacodynamics model, which
shows encouraging pilot runs on a few patients. Any
such model needs to be informed by data from the
unique patient for whom we wish to determine the best
therapeutic regime. We have shown that it is possible
to estimate personalized parameters with data com-
patible with clinical practice and use them to make re-
liable predictions of the effect of therapy for a unique
and single patient.
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